XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses        
Research and development $ 7,953 $ 11,662 $ 16,243 $ 22,787
General and administrative 15,384 7,201 28,023 13,195
Total operating expenses 23,337 18,863 44,266 35,982
Other operating income 13 577 342 782
Loss from operations (23,324) (18,286) (43,924) (35,200)
Other income/(expense):        
Interest income 523 635 1,079 1,410
Interest expense (12) (12) (25) (24)
Research and development incentives 1,342 693 1,644 1,287
Other income 320 20 395 20
Total other income, net 2,173 1,336 3,093 2,693
Loss before income tax (21,151) (16,950) (40,831) (32,507)
Tax benefit 25 7 47 44
Net loss (21,126) (16,943) (40,784) (32,463)
Net loss attributable to noncontrolling interest 2 12 12 43
Net loss attributable to Barinthus Biotherapeutics plc shareholders $ (21,124) $ (16,931) $ (40,772) $ (32,420)
Weighted-average ordinary shares outstanding, basic (in shares) 40,343,521 39,041,111 40,304,584 38,907,296
Weighted-average ordinary shares outstanding, diluted (in shares) 40,343,521 39,041,111 40,304,584 38,907,296
Net loss per share attributable to ordinary shareholders, basic (in usd per share) $ (0.52) $ (0.43) $ (1.01) $ (0.83)
Net loss per share attributable to ordinary shareholders, diluted (in usd per share) $ (0.52) $ (0.43) $ (1.01) $ (0.83)
Net loss $ (21,126) $ (16,943) $ (40,784) $ (32,463)
Other comprehensive gain/(loss) – foreign currency translation adjustments 8,295 164 12,941 (1,413)
Comprehensive loss (12,831) (16,779) (27,843) (33,876)
Comprehensive loss/(gain) attributable to noncontrolling interest (5) 11 2 39
Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders $ (12,836) $ (16,768) $ (27,841) $ (33,837)